ReviewInternational journal of biomedical imaging2026
Personalized PET Imaging in Gastric Cancer: An Umbrella Review of Meta-Analyses to Guide Radiopharmaceutical Selection and Clinical Indication.
Review in International journal of biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Personalized PET Imaging in Gastric Cancer: An Umbrella Review of Meta-Analyses to Guide Radiopharmaceutical Selection and Clinical Indication.International journal of biomedical imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer remains a leading cause of cancer-related morbidity and mortality worldwide, and accurate imaging is critical for diagnosis, staging, recurrence detection, and prognostic assessment. Positron emission tomography (PET), traditionally performed using Objective: We are aimed at synthesizing and appraise meta-analytic evidence on PET imaging in gastric cancer, with a focus on radiopharmaceutical-specific performance by clinical indication and certainty of evidence to inform personalized tracer selection. Methods: An umbrella review was conducted in accordance with PRISMA 2020. The protocol was prospectively registered in the Open Science Framework (OSF). PubMed, Scopus, and Web of Science were searched from inception to December 2025 for systematic reviews and meta-analyses evaluating PET imaging in gastric cancer. Outcomes included diagnostic accuracy, staging and restaging performance, recurrence detection, prognostic associations, methodological quality (AMSTAR-2), and certainty of evidence (GRADE). Results: Eleven meta-analyses published between 2011 and 2025 were included. FDG PET/CT demonstrated moderate diagnostic performance overall, with high specificity but limited sensitivity for lymph node and peritoneal metastases, while retaining moderate certainty for prognostic assessment based on standardized uptake value (SUV)-derived metrics. In contrast, Conclusions: Available meta-analytic evidence suggests an indication-driven, personalized approach to PET imaging in gastric cancer. FDG PET remains useful for prognostic stratification and selected recurrence settings, whereas FAPI PET appears to offer higher diagnostic sensitivity for staging and restaging, particularly for peritoneal disease. Nevertheless, the overall certainty of evidence remains limited by heterogeneity, indirectness, and the absence of updated de novo pooled analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.